GSK Arexvy protects from RSV over 3 full seasons
GSK Says RSV Vaccine Arexvy Showed Positive Efficacy Data Over Three Seasons
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...
The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...
GSK shared new Phase III data on Arexvy, its RSV vaccine, at the 2024 CHEST annual meeting. Results show a single dose of ...
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...
In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...
GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...
RSV hospitalizes thousands of people in the US every year. Three new vaccines could help stem the spread, but there are ...
London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback